You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
α2-adrenoceptor agonist that does not cross the blood brain barrier. Displays ~ 120-fold selectivity for α2 receptors over α1 receptors and acts predominantly at non-α2A-adrenoceptors which may be of the α2C subtype. Antinociceptive; increases tail-flick latencies in Sasco and Harlan rats.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 253.77. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.94 mL||19.7 mL||39.41 mL|
|5 mM||0.79 mL||3.94 mL||7.88 mL|
|10 mM||0.39 mL||1.97 mL||3.94 mL|
|50 mM||0.08 mL||0.39 mL||0.79 mL|
References are publications that support the biological activity of the product.
Takano and Yaksh (1992) Characterization of the pharmacology of intrathecally administered alpha-2 agonists and antagonists in rats. J.Pharmacol.Exp.Ther. 261 764 PMID: 1349648
Celly et al (1999) Cardiopulmonary effects of the α2-adrenoceptor agonists medetomidine and ST-91 in anesthetized sheep. J.Pharmacol.Exp.Ther. 289 712 PMID: 10215644
Graham et al (2000) Synergistic interactions between two α2-adrenoceptor agonists, dexmedetom. and ST-91, in two substrains of Sprague-Dawley rats. Pain 85 135 PMID: 10692612
If you know of a relevant reference for ST 91, please let us know.
View Related Products by Product Action
Keywords: ST 91, ST 91 supplier, α2-adrenoceptor, alpha2-adrenoceptors, a2-adrenoceptors, α2-Adrenergic, alpha2-Adrenergic, a2-adrenergic, agonists, putative, α2C-adrenoceptor, alpha2C-adrenoceptors, α2c-adrenergic, alpha2c-adrenergic, a2c-adrenoceptor, a2c-adrenergic, Receptors, ST, Adrenergic, Alpha-2, 2638, Tocris Bioscience
1 Citation for ST 91
Citations are publications that use Tocris products. Selected citations for ST 91 include:
Kim et al (2011) Icilin-evoked behavioral stimulation is attenuated by alpha2-adrenoceptor activation. Brain Res 1384 110 PMID: 21315691
Do you know of a great paper that uses ST 91 from Tocris? Please let us know.
Reviews for ST 91
There are currently no reviews for this product. Be the first to review ST 91 and earn rewards!
Have you used ST 91?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.